Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

4.5 (435) · $ 31.00 · In stock

Current Treatment Landscape and Emerging Therapies for Metastatic Triple-Negative Breast Cancer

Frontiers Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer

IJMS, Free Full-Text

Pharmaceuticals, Free Full-Text

PDF) Immunotherapeutic Interventions of Triple Negative Breast Cancer

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Full article: The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022

Cancers, Free Full-Text

Cancers, Free Full-Text

Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer, Experimental Hematology & Oncology

Long Non-Coding RNAs in Triple-Negative Breast Cancer

You may also like